查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1186540

紅生物科技的全球市場 - 現狀分析與預測(2022年～2028年)

Red Biotechnology Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球紅生物科技的市場規模在預測期間內預計將以約6％大幅成長。罕見疾病的增加、病毒突變的爆發、政府和私人組織對生物製品行業的投資增加等都是促進市場增長的因素。

本報告提供全球紅生物科技市場相關調查分析，市場規模與預測分析，主要趨勢和機會，企業簡介等資訊。

目錄

第1章 市場簡介

第2章 調查手法·前提條件

第3章 市場摘要

第4章 摘要整理

第5章 紅生物科技市場上COVID-19影響

第6章 紅生物科技市場收益(2020年～2028年)

第7章 市場考察:各用途

  • 生物醫藥品的生產
  • 基因治療
  • 藥物基因體學
  • 遺傳基因檢驗
  • 其他

第8章 市場考察:各產品類型

  • 基因重組醫藥品
  • 人體疫苗
  • 血液製劑
  • 診斷劑
  • 個人化醫療
  • 其他

第9章 市場考察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他的北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他的亞太地區
  • 其他地區

第10章 紅生物科技的市場動態

  • 推動市場要素
  • 市場課題
  • 影響的分析

第11章 紅生物科技市場機會

第12章 紅生物科技市場趨勢

第13章 需求端和供應端的分析

  • 需求端分析
  • 供應端分析

第14章 價值鏈分析

第15章 競爭模式

  • 競爭情形
    • 波特的五力分析

第16章 企業簡介

  • Pfizer Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd
  • Celgene Corporation
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Amgen Inc.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • CSL Limited

第17章 免責聲明

簡介目錄
Product Code: UMME211346

The global red biotechnology market is expected to grow at a significant rate of around 6% during the forecast period. Biopharmaceuticals are complex medicines made from living cells or organisms, often produced using cutting-edge biotechnological methods. The reliability and safety of biopharmaceutical products along with their ability to treat rare diseases are among the important factors responsible for the market growth of the biopharmaceutical industry. Furthermore, the rising number of orphan diseases, the occurrence of mutation in the viruses, and increasing investments in the biologics industry by government & private organizations are also contributing factors to the market growth of red biotechnology. For instance, in July 2022, vaccine maker Biological E announced its expansion plans for investment of over Rs 1,800 crore.

Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co. Inc., and CSL Limited are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

 

Insights Presented in the Report:

"Amongst Application, pharmacogenomics category to witness higher CAGR during the forecast period"

Based on the application, the market has been categorized into biopharmaceutical production, gene therapy, pharmacogenomics, genetic testing, and others. The pharmacogenomics category is expected to witness a higher CAGR during the forecast period. The rising number of genetic disorders along with the increasing number of autoimmune disorders and the rising biotechnology industry in developing nations is responsible for the segmental growth of pharmacogenomics.

"Amongst Product Type, human vaccines to hold a significant share in the market in 2020"

Based on the product type, the market has been categorized into gene recombinant drugs, human vaccines, blood products, diagnostics reagents, personalized medicines, and others. Among them, the human vaccines segment is expected to have significant growth in the market during the forecast period. The rising government efforts to increase vaccination along with vaccines provide long-term solutions against the disease is attributed to the growth of the market. For instance, as per the national health mission, Universal Immunization Program (UIP) is one of the largest public health programs targeting close of 2.67 crore newborns and 2.9 crore pregnant women annually.

"North America to hold a dominant share in the market"

For a better understanding of the market adoption of the red biotechnology industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global red biotechnology market. This is mainly attributed to the presence of major economies along with the higher R&D investment in the rising biotechnology industry in the region. Furthermore, the launch of various treatment and biopharmaceutical drugs is also an important reason for the considerable growth of the regional growth of the red biotechnology industry. For instance, in June 2021, Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™ for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients who have developed hypersensitivity to E. coli-derived asparaginase.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global red biotechnology market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Red Biotechnology Market
  • 2.2. Research Methodology of the Red Biotechnology Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE RED BIOTECHNOLOGY MARKET

6 RED BIOTECHNOLOGY MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY APPLICATION

  • 7.1. Biopharmaceutical Production
  • 7.2. Gene therapy
  • 7.3. Pharmacogenomics
  • 7.4. Genetic Testing
  • 7.5. Others

8 MARKET INSIGHTS BY PRODUCT TYPE

  • 8.1. Gene Recombinant Drugs
  • 8.2. Human Vaccines
  • 8.3. Blood Products
  • 8.4. Diagnostics Reagents
  • 8.5. Personalized Medicines
  • 8.6. Others

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10 RED BIOTECHNOLOGY MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 RED BIOTECHNOLOGY MARKET OPPORTUNITIES

12 RED BIOTECHNOLOGY MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

  • 15.1. Competitive Landscape
    • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

  • 16.1. Pfizer Inc.
  • 16.2. AstraZeneca PLC
  • 16.3. F. Hoffmann-La Roche Ltd
  • 16.4. Celgene Corporation
  • 16.5. Takeda Pharmaceutical Company Limited
  • 16.6. Biogen Inc.
  • 16.7. Amgen Inc.
  • 16.8. Gilead Sciences Inc.
  • 16.9. Merck & Co. Inc.
  • 16.10. CSL Limited

17 DISCLAIMER